Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York City
04 févr. 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market
03 janv. 2020 13h27 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market
31 déc. 2019 11h30 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market
19 déc. 2019 13h44 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
18 déc. 2019 09h05 HE
|
Onconova Therapeutics, Inc.
Proceeds provide sufficient funds to extend operations and ongoing trials late into the fourth quarter of 2020Company does not intend to raise additional capital for ninety days following the closing...
Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand
18 déc. 2019 09h00 HE
|
Onconova Therapeutics, Inc.
Specialised Therapeutics receives exclusive license to commercialize rigosertib in Australia and New ZealandOnconova to be eligible to receive up to US $30.4 million in clinical, regulatory, and...
Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil
17 déc. 2019 07h30 HE
|
Onconova Therapeutics, Inc.; Pint Pharma
The INSPIRE Trial enters the final stage of enrollment after surpassing 90% of the required number of randomized patients in November 2019 Pint Pharma Facilitates Opening of Phase 3 INSPIRE Trial in...
Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market
10 déc. 2019 15h07 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting
09 déc. 2019 09h00 HE
|
Onconova Therapeutics, Inc.
Genomic Profiling at Study Entry in Patients with Higher Risk Myelodysplastic Syndrome (HR-MDS) Following Hypomethylating (HMA) Failure: Results From the INSPIRE Trial, including RAS and other...
Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
09 déc. 2019 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...